Predicting Hepatic OATP1B1 and OATP1B3 Inhibition

Why hepatic OATP inhibition can change two concentrations in opposite directions

OATP1B1 and OATP1B3 mediate uptake of some compounds from blood into hepatocytes. If an inhibitor reduces this uptake, less substrate may reach hepatic metabolism or biliary elimination. Plasma exposure can therefore increase. At the same time, the reduced entry into hepatocytes can lower the liver concentration. The size and even the direction of these changes depend on the substrate’s other uptake routes, hepatic elimination, and nonhepatic clearance.

A useful first calculation is a deliberately simple, linear model that connects plasma concentration, hepatic uptake, and irreversible hepatic loss. It is not a complete liver PBPK model: it treats the liver as a single well-mixed compartment and uses effective clearances. Its purpose is to show how an OATP-mediated change can affect both systemic exposure and the concentration available within the liver.

The model assumes linear, concentration-independent clearances; a steady state in the liver and plasma; and a single unbound concentration basis for the hepatic exchange calculation. It represents uptake as a clearance-driven concentration-gradient process. In a compound with multiple entry routes, \(U\) is the sum of the relevant effective uptake clearances, including any uptake not mediated by OATP1B1 or OATP1B3. These assumptions make the equations useful for a first prediction, but they should not be confused with a detailed description of transporter kinetics or liver zonation.

Deriving the effective hepatic clearance

In this representation, hepatic uptake from plasma is proportional to the difference between plasma and hepatocyte concentration. At steady state, uptake into the hepatocyte balances irreversible hepatic elimination. The net amount removed from plasma through the modeled hepatic pathway is the amount eliminated within the liver.

Rearranging gives the hepatocyte-to-plasma concentration ratio. Substituting that relationship into the hepatic elimination flux gives the effective hepatic clearance.

The expression \(UM/(U+M)\) is the effective clearance of two sequential limitations: substrate must first enter the liver and then be eliminated there. It is smaller than either \(U\) or \(M\), because both processes constrain net hepatic removal. At steady state, the plasma balance is \(R=(CL_{other}+CL_{hep,eff})C_{p,u}\). Thus, when the input rate and clearances are fixed, the model predicts plasma and hepatocyte concentrations as follows.

This result explains why the two concentrations need not move together. Inhibition lowers \(U\), which lowers the liver-to-plasma ratio \(U/(U+M)\). It also lowers effective hepatic clearance, which can raise \(C_{p,u}\). The liver concentration depends on both changes, so it must be recalculated rather than inferred from the plasma change alone.

Representing OATP1B1 or OATP1B3 inhibition

For a simple competitive inhibition representation, an inhibited OATP component can be scaled by the unbound inhibitor concentration at the hepatic uptake site. If \(I_u\) is that concentration and \(K_i\) is the inhibition constant, the remaining activity factor is \(1/(1+I_u/K_i)\). This assumes the stated competitive form is suitable and that inhibitor exposure is adequately represented by a constant site concentration. In practice, the relevant inputs should be supported by the available in vitro evidence and site-exposure estimate.

For selective OATP1B3 inhibition, apply the corresponding factor to \(U_{1B3}\), not automatically to all uptake. If both isoforms are inhibited, scale each component using its own inhibition input. Any unaffected OATP component and other uptake routes remain in the total \(U\). The calculation requires an explicit distinction between the inhibited transporter clearance and residual uptake; treating all hepatic entry as one fully inhibited pathway can exaggerate the effect.

How substrate pathway contributions shape the prediction

The effect of inhibiting one transporter depends on how much that transporter contributes to total uptake. The next example keeps residual uptake explicit. It also illustrates why a large fractional inhibition of one isoform does not necessarily produce a large change in total hepatic uptake or systemic exposure.

When hepatic uptake is a stronger limitation

The ratio of uptake to hepatic elimination helps explain how inhibition affects liver concentrations. If \(U\) is already much smaller than \(M\), uptake strongly limits hepatic entry. A further reduction in uptake can sharply reduce the liver-to-plasma ratio. The effect on plasma exposure still depends on how important the hepatic pathway is relative to all systemic clearance.

Assumptions, diagnostics, and alternatives

A prediction from this model is most interpretable when its assumptions are plausible and its inputs are supported. Check that the substrate is a relevant substrate of the transporter being inhibited, that the inhibitor concentration used corresponds to the hepatic site, and that the clearance components are defined on consistent unbound and volume bases. Confirm that the predicted total uptake remains positive and that residual uptake is not inadvertently removed. If the calculation predicts an implausiblely large effect, inspect the fraction of total uptake assigned to the inhibited isoform and the relative sizes of \(M\) and \(CL_{other}\).

The steady-state equations also assume linear behavior. Concentration-dependent transporter saturation, changing inhibitor concentrations over time, or a substrate with important active metabolites can invalidate the simple calculation. A single steady-state comparison cannot describe the onset and offset of an interaction, nor can this model predict a spatially varying liver concentration. In those settings, a time-resolved PBPK model with suitable compartments and processes is more appropriate. Such a model requires additional data and assumptions; its added complexity does not by itself ensure a more reliable prediction.

A common alternative is to apply a single empirical fold-change to plasma exposure. That can summarize a measured interaction but does not show how uptake, hepatic elimination, and nonhepatic clearance combine, and it does not directly predict liver concentration. The simple clearance model presented here makes those dependencies explicit, while a fuller PBPK model can represent spatial and temporal detail. Neither approach removes the need to justify transporter assignment and parameter values.